Protective effects of high-density lipoprotein against oxidative stress are impaired in haemodialysis patients

Nephrology Dialysis Transplantation

Volumn 15, Issue 3, 2000, Pages 389-395

  Morena, Marion ^a   Cristol, Jean Paul ^a   Dantoine, Thierry ^b   Carbonneau, Marie Annette ^a   Descomps, Bernard ^a   Canaud, Bernard ^a  

^a UNIV MONTPELLIER   (France)

^b UNIVERSITY OF LIMOGES   (France)

Author keywords

High density lipoprotein; Lipid peroxidation; Low density lipoprotein

Indexed keywords

ALKADIENE; APOLIPOPROTEIN A1; BUFFER; COPPER; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL TRANSPORT; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME DEFECT; FEMALE; HEMODIALYSIS; HUMAN; KINETICS; LIPID PEROXIDATION; LIPOPROTEIN BLOOD LEVEL; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL;

ADULT; AGED; COPPER; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LIPIDS; LIPOPROTEINS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; OXIDATION-REDUCTION; OXIDATIVE STRESS; RENAL DIALYSIS;

EID: 0034004959     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/15.3.389     Document Type: Article

References (47)

1. Lindner A, Charra B, Sherrard D, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974; 290: 697-701
2. Braun WE. Long term complications of renal transplantation. Kidney Int 1990; 37: 1363-1378
3. London GM, Drüeke TB. Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney Int 1997; 51: 1678-1695
4. Chan MK, Varghese Z, Moorhead JF. Lipid abnormalities in uremia, dialysis, and transplantation. Kidney Int 1981; 19: 625-637
5. Attman PO, Alaupovic P. Lipid and apolipoprotein profiles of uremic dyslipoproteinemia. Relation to renal function and dialysis. Nephron 1991; 57: 401-410
6. Sutherland WHF, Corboy J, Walker RJ, Robertson MC, Ball MJ. Cell cholesterol transport to plasma in blood from patients with renal failure or a kidney transplant. Nephrol Dial Transplant 1995; 10: 358-365
7. Rajman I, Harper L, McPake D, Kendall M, Wheeler D. Low-density lipoprotein subfraction profiles in chronic renal failure. Nephrol Dial Transplant 1998; 13: 2281-2287
8. O'Neal D, Lee P, Murphy B, Best J. Low-density lipoprotein particle size distribution in end-stage renal disease treated with hemodialysis or peritoneal dialysis. Am J Kidney Dis 1996; 49: 488-493
9. Dejager S, Bruckert E, Chapman MJ. Dense low-density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia. J Lipid Res 1993; 34: 295-308
10. Loughrey CM, Young IS, Lightbody JH, McMaster D, McNamee PT, Trimble ER. Oxidative stress in haemodialysis. Q J Med 1994; 87: 679-683
11. Paul JL, Sall ND, Soni . et al. Lipid peroxidation abnormalities in hemodialysed patients. Nephron 1993; 64: 106-109
12. Saint-Georges MD, Bonnefont DJ, Bourely BA et al. Selenium deficiency correction in hemodialysed patients. Kidney Int 1989; 27: S274-S277
13. Cristol JP, Canaud B, Rabesandratana H, Gaillard I, Serre A, Mion C. Enhancement of reactive oxygen species production and cell surface markers expression during haemodialysis. Nephrol Dial Transplant 1994; 9: 389-394
14. Himmelfarl J, Lazarus M, Hakim R. Reactive oxygen species production by monocytes and polymorphonuclear leukocytes during dialysis. Am J Kidney Dis 1991; 17: 271-276
15. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996; 49: 1304-1313
16. Dean RT, Fu S, Stocker R, Davies MJ. Biochemistry and pathology of radical-mediated protein oxidation. Biochem J 1997; 324 (Pt 1): 1-18
17. Witko-Sarsat V, Friedlander M, Nguyen Khoa T et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998; 161: 2524-2532
18. Witko-Sarsat V, Nguyen-Khoa T, Jungers P, Drueke TB, Descamps-Latscha B. Advanced oxidation protein products as a novel molecular basis of oxidative stress in uraemia. Nephrol Dial Transplant 1999; 14 [Suppl 1]: 76-78
19. Miyata T., Kurokawa K., van Ypersele de Strihou C. Carbonyl stress and long-term uremic complications. Adv Nephrol Necker Hosp 1998; 28: 311-319
20. Ceballos-Picot I, Witko-Sarsat V, Merad-Boudia M et al. Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Radic Biol Med 1996; 21: 845-853
21. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyong cholesterol. Modifications of low-density lipoproteins that increase its atherogenicity. N Engl J Med 1989; 320: 915-924
22. Esterbauer H, Gebicki J, Puhl H, Jürgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med 1992; 13: 341-390
23. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-126
24. Maggi E, Bellazzi R, Falaschi F et al. Enhanced LDL oxidation in uremic patients: an additional mechanism for accelerated atherosclerosis? Kidney Int 1994; 45: 876-883
25. Sutherland W, Walker R, Ball M, Stapley S, Robertson M. Oxidation of low-density lipoproteins from patients with renal failure or renal transplants. Kidney Int 1995; 48: 227-236
26. Loughrey CM, Young IS, McEneny J et al. Oxidation of low-density lipoprotein in patients on regular haemodialysis. Atherosclerosis 1994; 110: 185-193
27. Westhuysen J, Saltissi D, Healy H. Oxidation of low-density lipoprotein in hemodialysis patients: effect of dialysis and comparison with matched controls. Atherosclerosis 1997; 129: 199-205
28. Panzetta O, Cominacini L, Garbin U et al. Increased susceptibility of LDL to in vitro oxidation in patients on maintenance haemodialysis: effects of fish oil and vitamin E administration. Clin Nephrol 1995; 44: 303-309
29. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991; 286: 152-154
30. Klimov AN, Gurevich VS, Nikiforova AA et al. Antioxidative activity of high-density lipoproteins in vivo. Atherosclerosis 1993; 100: 13-18
31. Schiavon R, De Fanti E, Giavarina D, Biasoli S, Cavalcanti G, Guidi G. Serum paraoxonase activity is decreased in uremic patients. Clin Chim Acta 1996; 247: 71-80
32. Dantoine TF, Debord J, Charmes JP et al. Decrease of serum paraoxonase activity in chronic renal failure. J Am Soc Nephrol 1998; 9: 2082-2088
33. Hasselwander O, McMaster D, Fogarty DG, Maxwell AP, Nicholls DP, Young IS. Serum paraoxonase and platelet-activating factor acetylhydrolase in chronic renal failure. Clin Chem 1998; 44: 179-181
34. Cristol JP, Bosc JY, Badiou S et al. Erythropoictin and oxidative stress in haemodialysis: beneficial effects of vitamin E supplementation. Nephrol Dial Transplant 1997; 12: 2312-2317
35. Verne N, Schumaker D, Puppione L. Sequential flotation ultra-centrifugation. Methods Enzymol 1986; 128: 155-170
36. Gieseg SP, Esterbauer H. Low-density lipoprotein is saturable by pro-oxidant copper. FEBS Lett 1994; 343: 188-194
37. Esterbauer H, Striegl G, Pulh H, Rothender M. Continuous monitoring of in vitro oxidation of human low-density lipoprotein. Free Radic Res Comm 1989; 6: 67-75
38. Morena M, Vaussenat F, Maggi MF, Canaud B, Cristol JP, Descomps B. Modélisation de la cinétique d'oxydation des LDL par un logiciel (logiciel NELOP) et validation dans une population à risques vasculaires. C R Soc Biol 1999; 193 (2): 211-217
39. Chan MK, Varghese Z, Persaud JW, Baillod RA, Moorhead JF. Hyperlipidemia in patients on maintenance hemo- and peritoneal dialysis. The relative pathogenetic roles of triglyceride production and triglyceride removal. Clin Nephrol 1982; 17: 183-190
40. Cattran DC, Fenton SSA, Wilson DR, Steiner G. Defective triglyceride removal in lipemia associated with peritoneal dialysis and hemodialysis. Ann Intern Med 1976; 85: 29-33
41. Senti M, Romero R, Pedro-Botet J, Pelegri A, Nogues X, Rubies-Prat J. Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure. Kidney Int 1992; 41: 1394-1399
42. Rajman I, Maxwell S, Cramb R, Kendall M. Particle size: the key to the atherogenic lipoprotein? Q J Med 1994; 87: 709-720
43. Chapman MJ, Bruckert E. The atherogenic role of triglycerides and small, dense low-density lipoproteins: impact of ciprofibrate therapy. Atherosclerosis 1996; 124 [Suppl]: S21-28
44. Sevanian A, Hwang J, Hodis H, Cazzolato G, Avogaro P, Bittolo-Bon G. Contribution of in vivo oxidized LDL to LDL oxidation and its association with dense LDL subpopulations. Arterioscler Thromb Vasc Biol 1996; 16: 784-793
45. Klimov AN, Kozhemiakin LA, Pleskov VM, Andreeva LI. Antioxidative effect of high-density lipoproteins in the oxidation of low-density lipoproteins. Biull Eksp Biol Med 1987; 103: 550-552
46. Mackness MI, Durrington PN. HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 1995; 115: 243-253
47. Mackness MI, Arrol S, Abbott C, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993; 104: 129-135